Division Chief
Karmanos Cancer Institute
BIOGRAPHICAL SKETCH
Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. DO NOT EXCEED FIVE PAGES.
NAME: Ammar Sukari, M.D.
POSITION TITLE: Assistant Professor, Department of Oncology
DEGREE(S): M.D.
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)
INSTITUTION AND LOCATION DEGREE
(if applicable)
Completion Date
MM/YYYY
FIELD OF STUDY
University of Aleppo Medical School, Syria M.D. 08/1998 Medicine
Al Assad University Hospital, Damascus, Syria Residency 08/1999 Internal Medicine
Wm Beaumont Royal Oak Hospital, Royal Oak, Michigan Residency 06/2004 Internal Medicine
Wm Beaumont Royal Oak Hospital, Royal Oak, Michigan Fellowship 07/2006 Medical Oncology
NOTE: The Biographical Sketch may not exceed five pages. Follow the formats and instructions below.
A. Personal Statement
I am a medical oncologist with special interest in head and neck cancer, lung cancer and immune-oncology. I am an active clinical and scientific member of the Karmanos Cancer Institute (KCI) with significant experience in clinical research. My research focus is in conducting clinical and translational research trials to improve treatment strategies for patients with lung and head and neck cancers. I am currently the local PI for multiple clinical trials in head and neck cancer at KCI. My clinical research experience spans over 10 years and includes both reviewing and prioritizing research protocols. In the past, I have assisted many residents and fellows with their research and training grants. Over the last 3 years, I have focused my research in cancer immunotherapy using checkpoint inhibitors.
B. Positions and Honors
12/06-06/10 St. John Hospital and Medical Center Oncology Staff Physician
12/07-06/10 Wm. Beaumont Hospital, Grosse Pointe, MI Oncology Staff Physician
05/08-11/08 Shores Internal Medicine Hem/Onc Staff Physician
07/10-07/11 Karmanos Crittenton Cancer Center Medical Director
06/06-Present Detroit Medical Center, Hematology/Oncology, Staff Physician
11/08-Present Wayne State University/Karmanos Cancer Institute Assistant Professor-Oncology, Staff
Physician
11/08-Present Crittenton Medical Center Oncology, Staff Physician
10/11-Present Karmanos Cancer Center Wertz Clinic, Medical Director
Memberships:
2004 – Present American Society of Clinical Oncology
Committees:
2014 – Present NCI Head & Neck Steering Committee (3 yr term)
2011 – Present UR Committee, Karmanos Cancer Institute
C. Contribution to Science
1) Developing new immunotherapy approaches in head and neck cancer patients.
Bauml J, Seiwert TY, Pfister DG, Worden F, Liu SV, Gilbert J, Saba NF, Weiss J, Wirth L, Sukari A, Kang H, Gibson MK, Massarelli E, Powell S, Meister A, Shu X, Cheng JD, Haddad R. Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. J Clin Oncol. 2017 M 22:JCO2016701524. doi: 10.1200/JCO.2016.70.1524.
Nagasaka M, Zaki M, Kim H, Raza SN, Yoo G, Lin HS, Sukari A. PD1/PD-L1 inhibition as a potential radiosensitizer in head and neck squamous cell carcinoma: a case report. J Immunother Cancer. 2016 Nov 15;4:83. PMID:27895920.
Sukari A, Nagasaka M, Al-Hadidi A, Lum LG. Cancer Immunology and Immunotherapy. Anticancer Res. 2016 Nov;36(11):5593-5606. Review. PMID: 27793882.
2) Developing new chemotherapy approaches to treat head and neck cancer patients.
Nagasaka M, Zaki M, Issa M, Kim H, Abrams J, Sukari A. Definitive chemoradiotherapy with carboplatin for squamous cell carcinoma of the head and neck. Laryngoscope. 2017 Mar 8. doi: 10.1002/lary.26554. Accrued patients, mentored trainee in writing and submitting the manuscript.
Jimeno A, Posner MR, Wirth LJ, Saba NF, Cohen RB, Popa EC, Argiris A, Grossmann KF, Sukari A, Wilson D, Zhang X, Sun J, Glasser C, Attie KM, Sherman ML, Pandya SS, Weiss J. A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer. 2016 Dec 1;122(23):3641-3649. doi: 10.1002/cncr.30317. PMID: 27648727.
Swiecicki PL, Bellile E, Sacco AG, Pearson AT, Taylor JM, Jackson TL, Chepeha DB, Spector ME, Shuman A, Malloy K, Moyer J, McKean E, McLean S, Sukari A, Wolf GT, Eisbruch A, Prince M, Bradford C, Carey TE, Wang S, Nör JE, Worden FP. A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer. Invest New Drugs. 2016 Aug;34(4):481-9. doi: 10.1007/s10637-016-0364-5. PMID: 27225873.
Sukari A, Al-Hajeili M, Salem M, Heilbrun L, Smith D, Yoo G, Jacobs JR, Lin HS, Kucuk O. Biweekly gemcitabine and paclitaxel in patients with relapsed or metastatic squamous cell carcinoma of the head and neck. Avicenna J Med. 2015 Apr-Jun;5(2):36-41. doi: 10.4103/2231-0770.154195. PMID: 25878965.
3) Developing new strategies combined with radiation therapy to treat head and neck cancer patients
Hurst NJ Jr, Pereira LM, Dominello MM, Dyson G, Laszewski P, Robinette N, Lin HS, Yoo G, Sukari A, Kim H. Pretreatment computed tomographic gross tumor volume as predictor of persistence of tracheostomy and percutaneous endoscopic gastrostomy tube in patients undergoing larynx preservation. Head Neck. 2016 Oct;38(10):1455-8. doi: 10.1002/hed.24458. PMID: 27131223.
Paximadis PA, Christensen ME, Dyson G, Kamdar DP, Sukari A, Lin HS, Yoo GH, Kim HE. Up-front neck dissection followed by concurrent chemoradiation in patients with regionally advanced head and neck cancer. Head Neck. 2012 Dec;34(12):1798-803. doi: 10.1002/hed.22011. PMID: 22307819.
Paximadis P, Yoo G, Lin HS, Jacobs J, Sukari A, Dyson G, Christensen M, Kim H. Concurrent chemoradiotherapy improves survival in patients with hypopharyngeal cancer. Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):1515-21. doi: 10.1016/j.ijrobp.2011.04.064. PMID: 21658855.
4) Treatment of rare malignancies.
Goncalves PH, Heilbrun LK, Barrett MT, Kummar S, Hansen AR, Siu LL, Piekarz RL, Sukari A, Chao J, Pilat MJ, Smith DW, Casetta L, Boerner SA, Chen A, Lenkiewicz E, Malasi S, LoRusso PM. A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma. Oncotarget. 2017 Mar 22. doi: 10.18632/oncotarget.16464.
Nagasaka M, Kukreja G, Abdulfatah E, Vaishampayan U, Sukari A. Role of Molecular Profiling in Diagnosis of Papillary Renal-cell Cancer Presenting as Cancer of Unknown Primary Site. Clin Genitourin Cancer. 2016 Dec 1. pii: S1558-7673(16)30340-8.doi:10.1016/j.clgc.2016.11.004 Accrued patients, mentored trainee in writing and submitting the manuscript.
Zaki M, Laszewski P, Robinette N, Saleh H, Raza N, Sukari A, Kim H. Unresectable Extraskeletal Myxoid Chondrosarcoma of the Neck: Early Tumor Response to Chemoradiotherapy. Cureus. 2015 Dec 24;7(12):e432. doi: 10.7759/cureus.432. PMID: 26848421.
Firwana B, Atassi B, Hasan R, Hasan N, Sukari A. Trastuzumab for Her2/neu-positive metastatic salivary gland carcinoma: Case report and review of the literature. Avicenna J Med. 2012 Jul;2(3):71-73. PMID: 23826550.
5) Social aspects of medicine.
Sahloul E, Salem R, Alrez W, Alkarim T, Sukari A, Maziak W, Atassi B. Cancer Care at Times of Crisis and War: The Syrian Example. Journal of Global Oncology by American Society of Clinical Oncology. DOI: 10.1200/JGO.2016.006189.
Svider PF, Blasco MA, Raza SN, Shkoukani M, Sukari A, Yoo GH, Folbe AJ, Lin HS, Fribley AM. Head and Neck Cancer, Underfunded and Understudied? Otolaryngol Head Neck Surg. 2017 Jan; 156(1):10-13. doi: 10.1177/0194599816674672. Participated in writing the manuscript.
For a full list of 20 peer-reviewed publications, please see the following link:
https://www.ncbi.nlm.nih.gov/pubmed/?term=ammar+sukari
D. Research Support
Ongoing Research Support
Lion Biotechnologies (PI)
2016-212; A Phase 2 Study to Evaluate the Safety, Tolerability and Efficacy of Cell Transfer Therapy Using Autologous Tumor Infiltrating Lymphocytes (LN-145) followed by IL-2 in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Merck (PI)
2015-031; A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
MedImmune (PI)
2015-075; A Phase II, Randomized, Open-Label, Multi-Center, Global Study of EDI4736 Monotherapy, Tremelimumab Monotherapy, and MEDI4736 in Combination with Tremelimumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
MedImmune (PI)
2015-074; A Phase II, Multi-Center, Single-Arm, Global Study of MEDI4736 Monotherapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
MedImmune (PI)
2014-130; A Phase I Study to Evaluate the Safety, Tolerability, and Efficacy of MED14736 in Combination with Tremelimumab or Tremelimumab Alone in Subjects with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Merck (PI) 12/15/14 – 12/14/17
A Phase II Clinical Trial of Single Agent Pembrolizumab (MK-3475) in Subjects with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Who Have Failed Platinum and Cetuximab
Role: PI
Karyopharm (PI) 09/30/14 – 09/29/17
A Phase 2, Open-label Study of the Safety and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients with Advanced Squamous Cell Carcinoma of Head and Neck, Lung, or Esophagus
Role: PI
Boehringer Ingelheim (PI) 07/09/14 – 07/08/17
A Randomised, Double-blind, Placebo-Controlled, Phase III Study to Evaluate the Efficacy and Safety of Afatinib (BIBW 2992) as Adjuvant Therapy after Chemo-Radiotherapy in Primary Unresected Patients with Stage III, IVa, or IVb Loco-regionally Advanced Head and Neck Squamous Cell Carcinoma
Role: PI
VentiRx (PI) 01/08/14 – 01/07/17
VRXP-A202: Randomized, Double-Blind, Placebo-Controlled Study of Chemotherapy Plus Cetuximab in
Combination with VTX-2337 in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head
and Neck
Role: PI
Acceleron (PI) 03/08/12 – 03/07/15
A041-03: An Open-label Phase 2 Study of ACE-041 in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Role: PI
Eli Lilly (PI) 04/28/10 – 04/30/15
I4E-MC-JXBD: A Randomized, Double-Blind, Phase 2 Safety Study of Cetuximab, Using ImClone versus Boehringer Ingelheim Manufacturing Processes, in Combination with Cisplatin or Carboplatin and 5-Fluorouracil in the First-Line Treatment of Patients with Locoregionally Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Role: PI
Completed Research Support
BioVex (PI) 10/22/10 – 07/29/11
006/09: A Phase 3 Randomized Trial of Concurrent Cisplatin and Radiotherapy With or Without ONCOVEXGM-CSF in Previously Untreated Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Role: PI
AstraZeneca (PI) 02/14/07 – 06/04/12
An International, Phase II Randomized, Double-Blinded, Placebo-Controlled, Multi-Center
Study to Assess the Efficacy of ZD6474 (Zactima (TM)) versus Placebo in Subjects with Unresectable
Locally Advanced or Metastatic Medullary Thyroid Cancer
Role: PI
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
